International Survey of Clinical Monitoring Practices in Pancreas and Islet Transplantation.

Abstract

BACKGROUND:

The long-term outcomes of both pancreas and islet allotransplantation have been compromised by difficulties in the detection of early graft dysfunction at a time when a clinical intervention can prevent further deterioration and preserve allograft function. The lack of standardized strategies for monitoring pancreas and islet allograft function prompted an international survey established by an International Pancreas and Islet Transplant Association/European Pancreas and Islet Transplant Association working group.

METHODS:

A global survey was administered to 24 pancreas and 18 islet programs using Redcap. The survey addressed protocolized and for-cause immunologic and metabolic monitoring strategies following pancreas and islet allotransplantation. All invited programs completed the survey.

RESULTS:

The survey identified that in both pancreas and islet allograft programs, protocolized clinical monitoring practices included assessing body weight, fasting glucose/C-peptide, hemoglobin A1c, and donor-specific antibody. Protocolized monitoring in islet transplant programs relied on the addition of mixed meal tolerance test, continuous glucose monitoring, and autoantibody titers. In the setting of either suspicion for rejection or serially increasing hemoglobin A1c/fasting glucose levels postpancreas transplant, Doppler ultrasound, computed tomography, autoantibody titers, and pancreas graft biopsy were identified as adjunctive strategies to protocolized monitoring studies. No additional assays were identified in the setting of serially increasing hemoglobin A1c levels postislet transplantation.

CONCLUSIONS:

This international survey identifies common immunologic and metabolic monitoring strategies utilized for protocol and for cause following pancreas and islet transplantation. In the absence of any formal studies to assess the efficacy of immunologic and metabolic testing to detect early allograft dysfunction, it can serve as a guidance document for developing monitoring algorithms following beta-cell replacement.

• Authors: Casey Ward, Jon S Odorico, Michael R Rickels, Thierry Berney, George W Burke 3rd, Thomas W H Kay, Olivier Thaunat, Pablo D Uva, Eelco J P de Koning, Helmut Arbogast, Hanne Scholz, Mark S Cattral, Robert J Stratta, Peter G Stock, for the International Pancreas and Islet Transplant Association Beta-Cell Replacement Therapy Monitoring Task Force
• Journal: Transplantation (Transplantation) Vol. 106 Issue 8 Pg. 1647-1655 (08 01 2022) ISSN: 1534-6080 [Electronic] United States
• PMID: 35019897 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural)
• Copyright: Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Chemical References

• Blood Glucose
• Glycated Hemoglobin A

Topics

• Blood Glucose (metabolism)
• Blood Glucose Self-Monitoring
• Diabetes Mellitus, Type 1 (diagnosis, surgery)
• Glycated Hemoglobin
• Humans
• Islets of Langerhans Transplantation (adverse effects, methods)
• Pancreas (metabolism)
• Pancreas Transplantation (adverse effects)